Belite Bio (Belite Bio) Debt-to-Revenue : N/A (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Belite Bio Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Belite Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Belite Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Belite Bio's annualized Revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.

Belite Bio Debt-to-Revenue Historical Data

The historical data trend for Belite Bio's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio Debt-to-Revenue Chart

Belite Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

N/A

Belite Bio Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial							N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Belite Bio's Debt-to-Revenue

For the Biotechnology subindustry, Belite Bio's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Belite Bio's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Belite Bio's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Belite Bio's Debt-to-Revenue falls into.

Belite Bio Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Belite Bio's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.308	+	0.578)	/	N/A
	=	N/A

Belite Bio's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Belite Bio Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Belite Bio's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Belite Bio (Belite Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

D01:Germany

Address

12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130

Website

https://www.belitebio.com

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.